Index

Notes: Page numbers in *italics* refer to figures, those in **bold** refer to tables. *vs.* indicates a comparison or differential diagnosis. The following abbreviations have been used in subentries:

- G-CSF: granulocyte colony-stimulating factor
- GM-CSF: granulocyte–macrophage colony-stimulating factor
- IL: interleukin
- MMP: matrix metalloproteinase
- NKT cells: natural killer T cells
- TGF-β: transforming growth factor β
- Th1 cells: T helper cells type 1
- Th2 cells: T helper cells type 2
- TLR: Toll-like receptor
- Treg: regulatory T cells

A
- A-122058 259
- AHR: airway hyperresponsiveness (AHR)
- AIRE: autoimmune regulator 40
- airway: mast cells 93–4, TGF-β effects 46–7, airway epithelial cells (AECs) see epithelial cells, airway fibrosis 237–41, collagen 237, extracellular matrix 237–8, TGF-β 238–9, airway hyperresponsiveness (AHR) 237, IL-17RB NKT cells 60, airway inflammation dendritic cells 8, prostanoids 278–9, airway remodeling 149–51, 237, 298, animal models 150, beneficial effects 151, fibroblasts 149, 151, MMPs 152, SD-208 153, smooth muscle cells 149, targets 150–1, TGF-β 150, airway smooth muscle (ASM) 163–71, 298, asthma pathogenesis 165–6, 167, chemokines 235
- AHR see airway hyperresponsiveness (AHR)
- AIRE (autoimmune regulator) 40
- airway inflammation dendritic cells 8
- prostanoids 278–9
- airway remodeling 149–51, 237, 298
- animal models 150
- beneficial effects 151
- fibroblasts 149, 151
- MMPs 152
- SD-208 153
- smooth muscle cells 149
- targets 150–1
- TGF-β 150
- airway smooth muscle (ASM) 163–71, 298
- asthma pathogenesis 165–6, 167
- chemokines 235

Acidic mammalian chitinase (AMCase) 178
- epithelial cells 143, 144
- acquired (adaptive) immune response B cells 68–9, mast cells 91–3, recognition 307–8, regulation 67
- activin A 238, 298
- activin receptor-like kinase (ALK) family 152
- AD: atopic dermatitis (AD)
- adalimumab 226
- ADAM33 244
- adenosine, mast cell activation 93
- adherens junctions 140
- adherens junctions (AJs) 139
- adoptive transfer experiments IL-15 202
- Th2 cells 17
- Th17 cells 199–200
- Treg in asthma 44
- adrenoceptors, β agonists see β₂-adrenergic agonists
- AECs see epithelial cells
- AER 001 (pitrakinra, IL-4 mutein, AEROVANT™) 22, 179–80
- AER 001 (pitrakinra, IL-4 mutein, AEROVANT™) 22, 179–80
- adrenoceptors, β₁ agonists see β₂-adrenergic agonists
- IL-5, effects of 190–1
- leukotrienes 288
- mast cell infiltration 79–80, 93–4, 298
- PGE₂ 276
- phenotype plasticity 163–5
- cell culture 164
- maturation 164, 164
- phenotype modulation 164
- prostanoids 276–8
- synthetic/proliferative 163
- treatment indications 167–8
- in vitro culture 163
- ALK see activin receptor-like kinase (ALK) family 152
- allele frequencies, IL-17RB polymorphisms 61–2
- allergic airway disease cytokines 189
- Th2 cells 17
- allergic airway inflammation IL-15 202
- IL-25 200–1
- allergic asthma, TNF 226–7
- allergic inflammation chemokines 253–5
- chronic see chronic allergic inflammation cytokines 7
- IL-10 effects 45–6

leukocyte recruitment 253–4
mast cells see mast cells
Th2 7
TLRs 7
allergic nonatopic asthma 109–11
allergic rhinitis
CD4+ cells 15
IL-18 34
allergies, IL-10 219
ALS (autoimmune lymphoproliferative syndrome) 39
alveolar macrophages 4
AMCase see acidic mammalian chitinase (AMCase)
AMD3100 259
AMD3389 259
AMG0317 22
amphiregulin
epithelial growth factor receptor binding 264
mast cells 93
ANG (angiogenin) 243
ANGI (angiopontin 1) 243
angiogenesis 241–4, 266
cancer therapies 246
definition 241
eosinophils 244
inducers 241
see also specific inducers
osteopontin 244
angiogenin (ANG) 243
angiopontin 1 (ANGI) 243
angiotatin 243–4
as therapy 246
animal models
airway remodeling 150
IL-3 189
IL-5 191
Th2 cells 17
TLSP 210–11
anrukinzumab 22
antiaggregation 130
antibody-secreting plasma cells (ASCs) 68, 190
anti-CD20 antibody (rituximab), B-cell depletion 72
anticycsteylin leukotrienes 95
antigen presentation
epithelial cells 142–3
Th2 differentiation 20
antigen-presenting cells (APCs)
dendritic cells 8, 9
IL-10 effects 215
TLRs 309
anti-IgE antibodies 95–6
anti-IL-1 antibodies 180
anti-IL-3 antibodies 192
anti-IL-3Ra antibodies 192
anti-IL-5 antibodies 73
see also mepolizumab (anti-IL-5)
anti-IL-13 antibodies 22, 246
anti-IL-25 antibodies 61
anti-inflammatory agents
severe asthma therapy 30
see also specific agents
antineukotirene drugs 290–1
future targets 291–2, 292
see also specific drugs
anti-p19 antibody 198
antisense RNA, IL-4R 22
anti-TNF medication, nonallergic asthma 113
APCs see antigen-presenting cells (APCs)
arachidonic acid metabolites, basophils 124
arginase 178
ASM see airway smooth muscle (ASM)
aspirin, COX-2 modifications 274–5
aspirin-induced asthma 274–5
asthma 109
airway remodeling see airway remodeling
allergen-specific Th1 cells 40
allergic nonatopic see allergic nonatopic asthma
animal models 113–17, 114
eosinophils 113, 115, 116
aspirin-induced 274–5
atopic (eosinophilic) 30, 109, 111
CD4+ cells 15
chronic, mast cells 88
definition 263
EGF receptor 264–5
eosinophil granule proteins 109
fetal 115
IL-10 45–6, 219
IL-18 34
infections 93
mast cells 297–8
NKT cells 63
nonallergic 109, 113
nonatopic (noneosinophilic) 30
pathogenesis 108–9
severe 30–1
super Th1 cells 32, 33
T cells 117
TGF-β effects 47
TNF blockade therapy 227–31
TLSP 210
vitamin D insufficiency 50, 51
atopic (eosinophilic) asthma 30, 109, 111
atopic dermatitis (AD) 111
histamine 94
IL-18 34
mouse models 95
Th2 cytokines 26
TLSP 209–10, 209, 210
atopic eczema see atopic dermatitis (AD)
atopy
cellular causes 111–13
signaling pathways 112
autoimmune diseases
mechanisms 27
self-reactive B cells 71
autoimmune lymphoproliferative syndrome (ALS) 39
autoimmune regulator (AIRE) 40
autoimmunity, B cells 71
B
B-1 cells
cell markers 68
characterization 71–2
contact sensitivity 72
development 68
pathogen product response 70
B7.1 see CD80 (B7.1)
B7.2 see CD86 (B7.2)
BADJ (bronchoalveolar duct junction) 144
basal fibroblast growth factor (bFGF) 156
BASC (bronchoalveolar stem cells) 143–4
basophils 123–37
cytokines 125
development 123, 127
differentiation, IL-5 190
functions 126
half-life 129–30
IgE-mediated signals as target 130–3
IgE production initiation 69
IL-3 effects 190
immediate hypersensitivity 69
inflammation regulation 124
innate immune response 124–6
leukotriene production 285, 287
mast cells vs. 123–4
mediator secretion 124, 127
receptors 127
CD123 127
chemokine receptors 124
as drug target 128–30
Fc  ε  RI 128
Fc  γ  RIIb 128
TLRs 125
regulation 127–8, 127
ST2 127
surface IgE 123
Th2 interaction 6, 8
BB1, basophil identification 123
B cell(s) 67–77
acquired immune response 68–9
autoimmunity 71
drug design 72–3
folicular 70
IgE production regulation 69–70
innate immune response 70–1
leukotriene production 287
LPS receptors 70–1
marginal zone 70
regulatory B cells 72–3
self-reactive 71
see also B-1 cells
B cell(s)
class switching 17
Th2 cytokines 17
B-cell receptors 307
β2-adrenergic agonists
allergic nonatopic asthma 110
fibroblast function 157
mechanisms 245
severe asthma therapy 30
bevacizumab 246
bFGF (basal fibroblast growth factor) 156
BION-1 192
BLT1 leukotriene receptor 287–8, 290
as drug target 292
BLT2 leukotriene receptor 290
BMP-7 247
bosentan 246
bronchial asthma, IL-4/IL-13 177
bronchial thermoplasty 168
bronchiolitis obliterans 150
bronchoalveolar duct junction (BADJ) 144
bronchoalveolar stem cells (BASC) 143–4
hkt 131
budesonide 245
BW245C 11
BX471 259
C
C5a, basophils 124–5
C57BL/6-Kit  ε  /Kit  ε  - mice 84–5
E-cadherin 139
epithelial barrier function 267
CAT-354 22
caveolin-1 22
CCL chemokines 255, 254
see also specific chemokines
CCL17 (TARC) chemokine 255
epithelial cells 143
Treg development 43
CCR1 chemokine receptor 256–7
antagonist 259
genetic deletions 256–7
CCR2 chemokine receptor 257
antagonist 259
CCR3 chemokine receptor 257
antagonist 259
CCR4 chemokine receptor 257–8
Treg development 43
CCR5 chemokine receptor antagonist 259
CCR6 chemokine receptor 257
CCR8 chemokine receptor 257–8
CD markers
airway epithelial cells 3
see also specific markers
CD1d 59
CD4+ T cells 15–16
IL-10 production 217–18
immune response regulation 67
knockout mouse models 117
leukotriene production 287
populations 27–8, 28
see also regulatory T cells (Tregs);
Th1 cells; Th2 cells
CD8+ T cells
IL-10 production 218–19
leukotriene production 287
TSLP–myeloid dendritic cells
interaction 208–9
CD14 311
CD16 (FcyRIII), eosinophils 109
CD19 71
CD23 (Fcy  ε  RII) 109
CD25 39, 40, 42, 48
CD28 40
CD32 (Fc  γ  RII) 109
CD36 310
CD38 42
CD40–CD40L
B-cell effects 92
IL-10 effects 219
Th2 cell effects 18–19, 69
CD43 68, 71
CD45RO 42
CD54 (ICAM-1) 143
CD62L 42
CD80 (B7.1)
epithelial cells 143
IL-10 effects 215
mast cells 91
T-cell development 40
CD80/CD86–CTLA-4/CD28 18–19
CD86 (B7.2)
epithelial cells 143
IL-10 effects 215
mast cells 91
T-cell development 40
CD89 see FcαRI (CD89)
CD95 (Fas) 39
CD95L 39
C/EBPα transcription factor
deficiency 152
cell activation, IL-5 190
cell culture, airway smooth muscle 164
cell differentiation, IL-3 189–90
cellular hyperplasia/hypertrophy, airway smooth muscle 166
certolizumab 226
chemokines 253–61
airway smooth muscle 255
allergic inflammation 253–5
basophils 124
classification 253, 254
CL chemokines 254
epithelial cells 143
fibroblasts 155
IL-17A/IL-17F effects 29
mast cells 91
mechanism of action 255
receptors 256
antagonists 259
severe asthma 30–1
see also specific chemokines
chitinases 178
Chlamydomphila pneumoniae infection 32
chondroitin sulfate, basophils 124
chronic allergic inflammation
fibroblast activation 153
mast cells 86–7
chronic asthma, mast cells 88
chronic obstructive pulmonary disease (COPD)
definition 263
EGF receptor 264
NKT cells 63
chronic urticaria 95
Churg–Strauss syndrome 113
leukotriene receptor 1 antagonists 291
chymase 299
CIA (collagen-induced arthritis) 27
ciclamilast 167
ciglitazone 245
CL chemokines 254
CLRs see C-type lectin receptors (CLRs)
cockroach allergens 301
colinilast (Arifl o®) 167
collagen
airway fibrosis 237
fibroblasts 238
PGE₂ 279
collagen-induced arthritis (CIA) 27
connective tissue growth factor (CTGF) 240
contact sensitivity (CS)
B-1 cells 72
drug design 72–3
mast cells 91
regulatory B cells 72
contractile airway smooth muscle 163
COPD see chronic obstructive pulmonary disease (COPD)
corticosteroid(s)
dendritic cells, effects on
inhaled, allergic nonatopic asthma 110
mast cell effects 96
mechanisms 220, 221
refractory asthma 51
Treg 50–1
see also glucocorticoids
corticosteroid resistance 30
IL-17RB polymorphisms 61–2
refractory asthma 51
Th-17-mediated airway inflammation 198
COX-1 (cyclooxygenase-1) 273
COX-2 see cyclooxygenase-2 (COX-2)
cPLA₂ see cytosolic phospholipase A₂ (cPLA₂)
Crohn disease 113
CRTh2/DP2 277
CTGF (connective tissue growth factor) 240
CTLA-4
dendritic cell–Treg interaction 41–2
Treg 42
C-type lectin receptors (CLRs) 308
Th2 cell differentiation 19
CX3CL 253, 254
CXCR8 chemokine 30
CXCL chemokines 253, 254
CXCL1 (ITAC) chemokine receptor 258
CXCL6 (GCP-2) chemokine receptor 258
CXCL8 chemokine see interleukin 8 (IL-8)
CXCL9 (Mig) chemokine
epithelial cells 143
receptor 258
CXCL10 (IP-10) chemokine
epithelial cells 143
mast cell activation 80
receptor 258
CXCL11 (I-TAC) chemokine 143
CXCL12 chemokine receptor 258
CXCL16 chemokine 143
CXCR1 chemokine receptor 258
CXCR3 chemokine receptor 258
CXCR4 chemokine receptor 258–9
fibroblasts 155
Cyclam 259
cyclooxygenase (COX) 155–6
cyclooxygenase-1 (COX-1) 273
cyclooxygenase-2 (COX-2)
modification by aspirin 275–6
prostanoids synthesis 273
cysteinyl leukotriene(s) (cysLTs) 285, 286, 287, 288–90
cysteinyl leukotriene receptor 1 (cysLT1) 287–8, 288–9
antagonists see leukotriene receptor 1 antagonists (LTRAs)
expression 289
signaling 289
cysteinyl leukotriene receptor 2 (cysLT2) 287–8, 289
as drug target 292, 292
cytosolic phospholipase A₂ (cPLA₂)
as drug target 292
inhibitor 227
leukotriene biosynthesis 285
cytokeratin-5 140
cytokeratin-19 140
cytokine(s)
allergic inflammation 7
IL-3 effects 190
pro-Th2, blocking 8–9
severe asthma 30–1
cytokine production
basophils 125
epithelial cells 143
mast cells 91, 297–8
NKT cells 59
super Th1 cells 31, 31
D
DAMPs see danger-associated molecular patterns (DAMPs)
danger-associated molecular patterns (DAMPs) 10, 308
blocking of 9
danger hypothesis 308
Daxas® (roflumilast) 167
DCs see dendritic cells (DCs)
Δdb/GATA mice 115–17
histochemistry 116
delayed-type hypersensitivity (DTH) 190

dendritic cells (DCs) 3–14, 4
activation 4–5
airway inflammation 8
CD markers 3–4
definition 3
depletion studies 6, 8
drug design 8–11
epithelial cell interaction 6
functions 3
as antigen-presenting cells 8, 9
blocking 9–11
sentinel function 5–6
Th2 induction 6
T tolerance induction 4–5
histamine effects 91
IL-10 production 217
leukotriene production 285–6, 287
plasmacytoid see plasmacytoid
dendritic cells (pDCs)
prostaglandin receptors 9
protease activated receptors 9
recruitment 8
subsets 3–4, 4
see also specific subsets
T-cell interaction 4–5

Der f 1 300
TLRs 312
Der p 1 300

dendritic cell activation 5
protease activity 267
TLRs 312
Der p 9, protease activity 267
desmosomes (Des) 140
apical junction complex 139
dipeptidyl peptidase (DPP10) 144
disodium cromoglycate, mast cell
analysis 84
D-L2 (programmed cell death-1
ligand-2) 91
DPP10 (dipeptidyl peptidase) 144
DP receptors 277
DTH (delayed-type hypersensitivity),
IL-3 190

E
E913 259
EAE (experimental autoimmune
encephalomyelitis) 27
eBP/Mac2, eosinophils 109
ECM see extracellular matrix
(ECM)
EDN (eosinophil-derived neurotoxin) 9
EGF see epithelial growth factor
(EGF)
EGFR see epithelial growth factor
receptor (EGFR)
eicosanoid lipid mediators, dendritic
cell migration 10–11
ELC (CCL19) chemokine 255
EMT (epithelial mesenchymal
transition) 151
EMTU (epithelial mesenchymal
 trophic unit) 265
endogenous proteases 297–300
animal models 299–300
see also mast cells; specific
proteases
endostatin 244
as therapy 246
endothelial cells, leukotriene
production 288
endothelin(s) 153
receptor blockers 246
endothelin 1 (ET-1) 240, 243
angiogenesis 246
asthmatic airways 166
mast cell activation 93
endotoxin, maternal infections 49
environmental allergens, GM-CSF
production 191
eosinophil-derived neurotoxin (EDN)
9
eosinophil esophagitis 112
eosinophil peroxidase (EPO),
knockout mouse models 115
eosinophils 107–21
airway inflammation 198–200
angiogenesis 244
associated conditions 107
asthma 108–9
animal models 113, 115, 116
Fc receptors 109
IL-5 effects 190
IL-10 effects 219
leukotriene production 285, 287
secondary granules 107, 108
T-cell interaction 107, 117
TGF-β secretion 238–9
eotaxin(s) 240
eotaxin-1 (CCL11) 255
asthma 16
IL-17A/IL-17F effects 29
production, basophils 124
eotaxin-2 (CCL24, 15E2) 255
asthma mouse models 115
eotaxin-3 (CCL26) 255
asthma 16
EP1 receptors 277
airway smooth muscle tone 276–7
EP2 receptors 277
EP3 receptors 277
airway smooth muscle tone 276–7
EP4 receptors 277
epiregulin 264
epithelial barrier 139–41
apical junction complex 139
epigeneic factors 144–5
gene factors 144–5
immune barrier 141–3, 142
normal vs. asthmatic airway
139–40, 141
stem cells 143–4
viral infections 267
epithelial cells 3–14, 139–48
activation
HDM fecal pellets 5, 6, 7
TLR4 5
antigen presentation 142–3
CD markers 3
chemokines 143
cytokine production 143
dendritic cell interaction 6
leukotriene production 288
lipopolysaccharide response 32
Th2 cytokines 17
epithelial growth factor (EGF) 240,
263–70
epithelial barrier function
266–7
expression 264–5
Forkhead transcription factor
expression 140
lung development 264
signaling 264
epithelial growth factor receptor
(EGFR) 156, 240, 263–4
asthma 264–5
COPD 264
epithelial wound repair 266
IL-8 synthesis 265–6
mucus secretion 267–8
epithelial mesenchymal transition
(EMT) 151
epithelial mesenchymal trophic unit
(EMTU) 265
epithelium see epithelial barrier
INDEX

Epstein–Barr virus infection, atopic dermatitis 112
ET-1 see endothelin 1 (ET-1)
etanercept 228
  adverse effects 231
  animal models 228
  clinical trials 229, 230–1, 230
  nonallergic asthma 113
  structure 226
everolimus 246
exogenous proteases 300–1
experimental autoimmune encephalomyelitis (EAE) 27
extracellular matrix (ECM)
  airway fibrosis 237–8
  asthma 165

F
Fas (CD95), T-cell development 39
FasL 39
FctR1 (CD89)
  basophils 128
  eosinophils 109
  mast cells 297
  MS4A2 subunit 128–9
  as target 128
FctRα, IL-3 effects 129
FctRI, mast cells 80, 85
FctRII (CD23), eosinophils 109
FcyRII (CD32), eosinophils 109
FcyRIIb, basophils 128
FcyRIII (CD16), eosinophils 109
FGF (fibroblast growth factor) 239
fibroblast growth factor (FGF) 239
fibroblasts 149–62
  airway remodeling 149, 151
  apoptosis 156–7, 157
  asthmatic airways 166
  chemokines 155
  chronic allergic inflammation 153
  collagen expression 238
  functional antagonists 157–8
  idiopathic pulmonary fibrosis 151
  leukotriene production 288
  models 152
  normal vs. asthmatic donors 151–2
  proliferation 156
targets 142
  see also specific targets
fibrocytes, leukotriene production 288
fibrogenesis, TGF-β 245
fibronectin (FN) 241
filaggrin, loss-of-function mutations 301–2
5-LO see 5-lipoxygenase (5-LO)
FLAP see 5-lipoxygenase-activating protein (FLAP)
fluticasone 245
5-LO see 5-lipoxygenase (5-LO)
folate, pregnancy effects 49
folicular (FO) B cells 70
follistatin 155
forkhead box P3 (FOXP3)
  IPEX syndrome 39
  mutation studies 47
  Treg 39, 42
  Treg in asthma 44
  Forkhead transcription factor, expression 140
  FOXP3 see forkhead box P3 (FOXP3)
  FP receptor 277
  FTY720 9–10
  functions 68–9
  furin 302
  fyn, as target 130–1
G
  gap junctions (GJ) 140
    apical junction complex 139
  GATA-3, Th2 differentiation 20, 20
  GATA-6/Wnt, epithelial cells 143
  GCP-2 (CXCL6) chemokine receptor 258
  G-CSF (granulocyte colony-stimulating factor) 30
    genetic analysis, IL-4/IL-13 177
    genetic deletions, CCR1 256–7
gG3, B-1 cells 68
  GITR (glucocorticoid-induced tumor necrosis factor response gene) 42
  GJ see gap junctions (GJ)
  glucocorticoid-induced tumor necrosis factor response gene (GITR) 42
glucocorticoids
  fibroblast function 157
  fibrosis/angiogenesis effects 244
  mechanism of action 244–5
  see also corticosteroid(s)
  GM-CSF see granulocyte–macrophage colony-stimulating factor (GM-CSF)
gobsmubab
  adverse effects 231
  clinical trials 229, 230, 231
  structure 226
GPR17 leukotriene receptor 289–90
granulocyte colony-stimulating factor (G-CSF) 30
granulocyte–macrophage colony-stimulating factor (GM-CSF) 187–96
allergic airway disease 189
  cell sources 191
drug design 9
  functions 188–9
  gene expression 187
  immunobiology 191–2
  intervention studies 192
  mast cells 80
  pleiotropy 188
  pulmonary homeostasis 188–9
  receptors 187–8
  redundancy 188
  specificity 188
  structure 187–8
  granzyme B 124
  grass pollen immunotherapy 50
  GRO-α 30
  growth factors, airway smooth muscle plasticity 164–5
  GSK-679586 22
  GW7845 247
H
halofuginone 247
hCLCA1 (human calcium-activated chloride channel 1) 178
HDACs (histone deacetylases) 144–5
HDM fecal pellets
  epithelial cell activation 5, 6, 7
  proteolytic activity 5
helminth infections, Th2 cells 40
  helper T cells see CD4+ T cells
hematopoietic stem cells
  leukotriene production 288
  mast cell development 79
heparin sulfate proteoglycans (HSPGs) 242
histamine 9
  atopic dermatitis 94
    production
    basophils 124
    mast cells 80, 85, 91
  histochemistry, mast cell analysis 84
histone deacetylases (HDACs) 144–5

HLA DR, CD4+ cells 15

house dust mite proteases 300–1
see also specific proteases

HSPGs (heparin sulfate proteoglycans) 242

human calcium-activated chloride channel 1 (hCLCA1) 178

hygiene hypothesis 51, 311–12

Treg 49

delayed-type hypersensitivity 190

immunoglobulin A (IgA), B-1 cells 68

immunoglobulin E (IgE) 68

antigen-specific production 69

class switching, IL-13 177–8

mast cell activation 85, 86–7

production

B-cell regulation 69–70

TNF upregulation 226

mmunoglobulin E (IgE) 68

antigen-specific production 69

class switching, IL-13 177–8

mast cell activation 85, 86–7

production

B-cell regulation 69–70

TNF upregulation 226

immunoglobulin G4 (IgG4), IL-10 effects 45, 49–50

immunoglobulin M (IgM) B-1 cells 68, 71

class switching 69

immunoglobulin(s), maturation 68–9

immunohistochemistry, mast cell analysis 84

immunologic memory 67

immunotherapy, IL-10 219–20, 220

inducible nitric oxide synthase (iNOS) 16

inducible regulatory T cells (iTreg) 217–18, 220

inducible T-cell co-stimulator ligand (ICOSL) 91

infections, asthma 93

infectious-type bronchial asthma, super Th1 cells 32–4

inflammation 67–8

basophils 124

inflammatory dendritic cells (iDCs) 4

infl iximab 228

animal models 228

clinical trials 229–30, 230

nonallergic asthma 113

structure 226

inhaled corticosteroids, allergic

nonatopic asthma 110

innate allergic immune response,

thymic stromal lymphopoietin

205–7

innate immune response

basophils 124–6

B cells 70–1

epithelial barrier 141–2

Nod-like receptors 67

receptors 307–8

TLRs 67, 70

TNF 225

integrins 154, 155

intercellular adhesion molecule 1

(iCAM1), mast cell activation

80

interferon-γ (IFN-γ)

functions 27

IL-10 effects 215

production, NKT cells 59

interferon regulatory factor 4 (IRF-4)

TLR signaling 309, 310

Treg development 43

interleukin 2 (IL-2)

receptor, CD4+ cells 15

Th2 differentiation 20

interleukin 3 (IL-3) 187–96

allergic airway disease 189

basophils 124

FcaRIα 129

functions 188–9, 189–90

gene expression 187

immunobiology 189–90

intervention studies 192

pleiotropy 188

pulmonary homeostasis 188–9

receptors 187–8

redundancy 188

specificity 188

structure 187–8

interleukin 4 (IL-4) 175–80, 241

actions of 177

B cells see below

IgE-mediated processes 17

mast cell development 79

Th2 cell activation 69

Th2 differentiation 21
### INDEX

- antagonists 179–80
- asthma 109
- B-cell effects 92
  - class switching 17
  - blocking 21–2
- bronchial asthma 176–7
- deficient mice 176
- genetic analysis 177
- mechanisms 177–9
- production
  - basophils 124, 125
  - IL-17R+ NKT cells 60
- receptors 175
- signal transduction 175–7
- transcriptions, NFAT-1 177
- interleukin 5 (IL-5) 187–96
  - actions 17, 188–9
  - allergic airway disease 189
  - asthma 109
  - mouse models 115
- B-cell effects 92
- gene expression 187
- immunobiology 190–1
- intervention studies 192
- pleiotropy 188
- production
  - IL-17R+ NKT cells 60
  - mast cells 80
  - pulmonary homeostasis 188–9
  - receptors 187–8
  - B-1 cells 68, 71
  - redundancy 188
  - specificity 188
  - structure 187–8
  - Th2 cells 16
- interleukin 6 (IL-6)
  - B-cell effects 92
  - IL-17A/IL-17F effects 29
  - production, mast cells 80
  - Th17 cell development 28
- interleukin 8 (IL-8)
  - as chemoattractant 30
  - neutrophils 266
  - IL-17A/IL-17F effects 29
  - production
    - basophils 124
    - epithelial growth factor receptor 265–6
  - receptor 258
- interleukin 9 (IL-9) 180–1
  - administration studies 180
  - expression 180
  - IgE-mediated processes 17
  - lack-of-function mice 180
  - mast cell development 79
  - signal transduction 180
  - Th2 effects 43
  - interleukin 10 (IL-10) 45–6, 215
  - actions of 215
  - CD40 219
  - eosinophils 219
  - IgG4 production 220
  - mast cell development 79
  - allergies 219
  - asthma 219
    - Treg 44
  - contact sensitivity 72
  - direct administration 221
  - expression 215
  - IgG4 effects 49–50
  - immunotherapy 219–20, 220
  - pharmacologic potential 220–1
  - receptors 215–16
  - signaling 215–17, 216
  - sources 40–1, 45, 217–19, 218
  - CD8+ T cells 218–19
  - dendritic cells 217
  - iTreg 220
  - macrophages 217
  - mast cells 80
  - NKT cells 59
  - Treg 217–18
  - Th2 effects 43
- interleukin 12 (IL-12)
  - as Th17 cells 29
  - production 28
  - Th17 cell development 28
- interleukin 13 (IL-13) 175–80, 241
  - basophil development 127
  - Th2 cell activation 69
  - asthma 109
- interleukin 15 (IL-15) 201–2
  - actions of 177
  - allergic asthma 29
  - antagonists 179–80
  - mechanisms 177–9
  - receptor IL-17R 29
  - Th17 cell development 29
  - interleukin 17A (IL-17A) 198
  - asthma 30
  - functions 29
  - neutrophils, effects on 62–3
  - interleukin 17B (IL-17B) 198
  - IL-25 binding 200
  - receptor polymorphisms 61–2, 62
  - interleukin 17F (IL-17F)
    - asthma 30
    - functions 29
  - interleukin 18 (IL-18)
    - IL-18R
      - infectious-type bronchial asthma 32
      - super Th1 cell induction 31
      - infectious-type bronchial asthma 33–4
  - interleukin 21 (IL-21), Th17 cells 28, 199
  - interleukin 23 (IL-23) 197
    - allergic asthma 30
    - mast cell effects 94
    - neutralization 198
    - Th17 cell development 28
  - interleukin 23 (IL-23)–Th17 cell axis 197–200, 198
  - eosinophilic airway inflammation 198–200
    - mechanisms 199
  - neutrophilic inflammation 197–8
  - interleukin 25 (IL-25) 198, 200–1
    - administration studies 200
  - allergic airway inflammation 200–1
    - deficient mice, AHR studies 61
    - drug design 9
  - expression studies 200–1
  - IL-17R+ NKT cells 60
  - infectious-type bronchial asthma 32
  - receptors 200
  - responsive cells 201
  - Th2 cell differentiation 19
  - interleukin 33 (IL-33)
    - basophils, effects on 127
    - drug design 9
INDEX

infectious-type bronchial asthma 32
NKT cell activation 63
Th2 cell differentiation 19
intestinal parasite infections, TSLP 210–11

in vitro analysis
airway smooth muscle 163
mast cells 83

in vivo analysis, mast cells 84

IP-10 see CXCL10 (IP-10) chemokine
IP receptor 277
IRF-4 see interferon regulatory factor 4 (IRF-4)
ITAC (CXCL1) chemokine receptor 258
I-TAC (CXCL11) chemokine 143

J
JAK1
IL-10 signaling 216
TSLP signal transduction 211
JAK2, TSLP signal transduction 211
JAK/STAT pathway, IL-4/IL-13 175, 176
Janeway, Charles 308

K
kininogen 299
knockout mice
PGE2 274
TNF blockade therapy 227

L
LAG-3 41–2
lamina propria 3
laminin-2 164–5
Langerhans cells 91
LARC (CCL20) chemokine 255
leukocyte immunoglobulin-like receptors (LIL) 124
leukocyte inhibitory receptor 7 (LIR-7) 128
leukocytes
homeostasis, TGF-β 46
recruitment 253–4

leukotriene(s) 285–95
actions 286–90, 287–8
biosynthesis 285–6, 286
dendritic cell migration 10–11
modifiers, allergic nonatopic asthma 110
receptors 287–8
synthesis 275
leukotriene B4 (LTB4) 287–8, 290
receptors 290
leukotriene C4 (LTC4) basophils 124
mast cells 80
leukotriene receptor 1 antagonists (LTRAs) 285, 290–1
allergic nonatopic asthma 110
Churg-Strauss syndrome 291
efficacy 291
LIL (leukocyte immunoglobulin-like receptors) 124
LILRA-2, basophils 124
linkage disequilibrium, IL-17RB polymorphisms 62
lipopolysaccharide receptors 308
lipopolysaccharide response, epithelial cells 32
5-lipoxygenase (5-LO)
as drug target 292–3
inhibitors 290, 291
allergic nonatopic asthma 110
leukotriene biosynthesis 285
5-lipoxygenase-activating protein (FLAP)
as drug target 292–3, 292
leukotriene biosynthesis 285
LIR-3 (LILRB-3), basophils, effects on 128
LIR-7 (leukocyte inhibitory receptor 7) 128
LTB4 see leukotriene B4 (LTB4)
LTC4 see leukotriene C4 (LTC4)
LTC4S, as drug target 292
LTRAs see leukotriene receptor 1 antagonists (LTRAs)
lung development, epithelial growth factor 264
lyn, as target 130

M
M2 macrophages, IL-10 production 217
Mac-1, B-1 cells 68
macrophage inflammatory protein 5 (MIP-5) 124
macrophages
alveolar 4
leukotriene production 285–6, 287
M2 macrophages, IL-10 production 217
NKT cell interactions 63
TLRs 309
TNF production 225
major basic protein (MBP), knockout mouse models 115
MAPK, TLR signaling 309, 310
marginal zone B cells 70
pathogen product response 70
mast cells 79–105
acquired immune response 91–3
activation 80, 81–2, 93
IgE-dependent 86–7
TSLP 206
adjuvant functions 92–3
airway 93–4
airway smooth muscle infiltration 298
allergic inflammation 7, 85–93
chronic 88, 90–1
IgE-dependent activation 85, 88
asthma 297–8
basophils vs. 123–4
bronchial epithelium association 93
chemokines 91, 255
chronic allergic inflammation 86–7
chronic asthma 88
chymase 301
contact hypersensitivity 91
co-stimulatory molecules 91
cytokine release 80, 91, 297–8
FceRI, 297
FceRI, 80
Fcγ signaling 90, 90
function manipulation 95–6
histamine 91
immediate hypersensitivity 69
leukotriene production 285, 287
maturation 82–3
mouse models 84–5
origins 79–80
protease conservation/evolution 299
see also specific proteases
skin 94–5
tissue distribution 79–80

325
trypase release 267, 298–9

in vitro analysis 83

in vivo analysis 84

mast cell-specific Cre mice 85

matrilysin 302

matrix metalloproteinase(s) (MMPs)

airway remodeling 152

MMP-2, angiogenesis 241

MMP-7, Treg development 42

MMP-9, angiogenesis 241

MMP-12, inflammation 243–4

Matzinger, Polly 308

MBP (major basic protein), knockout mouse models 115

mCLCA3 (mouse calcium-activated chloride channel 3) 178

MCP-2 (CCL8) chemokine 255

MCP-4 (CCL13) chemokine 255

MD-2, TLR4 signaling control 311

MDC see CCL22 (MDC) chemokine

mDCs see myeloid dendritic cells (mDCs)

mepolizumab (anti-IL-5) 22

allergic nonatopic asthma 110

metalloproteinases, IL-17A/IL-17F effects 29

Mig see CXCL9 (Mig) chemokine

MILR1444 22

MIP-1α, basophils 124

MIP-5 (macrophage inflammatory protein 5) 124

MK2−/− mice 153

MMP-2 (matrix metalloproteinase 2), angiogenesis 241

MMP-2, angiogenesis 241

MMP-7, Treg development 42

MMP-9, angiogenesis 241

MMP-12, inflammation 243–4

Montelukast 290

allergic nonatopic asthma 110

disease associations 265

IL-17A effects 62–3

IL-17A/IL-17F effects 29

inflammation, IL-23–Th17 cell axis 197–8

leukotriene production 285, 287

NFAT-1, IL-4 transcription 177

NFκB pathway

immunoglobulin class switching 69–70

Th17 cell transfer studies 200

TLR signaling 309, 310

TSLP production 211

NGF (nerve growth factor) 243

nitric oxide synthase (NOS), inducible 16

NJ.1726 mouse 113

NLRs see Nod-like receptors (NLRs)

NOD2, mast cell activation 80

Nod-like receptors (NLRs)

innate immune response 67

NKT cell activation 63

NODS (nucleotide-binding oligomerization domains) 141

nonallergic asthma 109, 113

nonatopic (noneosinophilic) asthma 30

nondeleterious cell tolerance 39

non-small cell lung cancer, EGF receptor 264

nonsteroidal anti-inflammatory drugs (NSAIDs), asthma precipitation 156

Notch 3, dendritic cell–Treg interaction 41–2

NSAIDs (nonsteroidal anti-inflammatory drugs), asthma precipitation 156

nucleotide-binding oligomerization domains (NODS) 141

Omalizumab 95

allergic nonatopic asthma 110–11

atopy 112, 113

basophils, effects on 123

clinical benefits 225–6

Syk expression 132–3

ONO-AE1–259 278

ONO-AEI-329 278

OPN see osteopontin (OPN)

osteopontin (OPN) 240

angio genesis 244

overexpression animal models, TSLP 210

OX40L

mast cells 91

TSLP–myeloid dendritic cells 207–8, 211–12

oxidant pollutants, epithelial barrier 139

ozone, IL-17R+ NKT cells 62–3

Mucosa pneumoniae infection 32
INDEX

P
P2Y12 289–90
as drug target 292
PAC (platelet-activating factor) 124
PAMPs see pathogen-associated molecular patterns (PAMPs)
papain 300
PAR-1 (protease-activated receptor 1) 301
PAR-2 see protease-activated receptor 2 (PAR-2)
parasite immunity, IL-3 190
PARs see protease-activated receptor(s) (PARs)
passage transfer experiments, IL-17R + NKT cells 60–1
PAMPs 67, 141, 308
mast cell activation 80
pattern recognition receptors (PRRs) 141, 308
NKT cell activation 63
TNF production 225
pDCs see plasmacytoid dendritic cells (pDCs)
PDGF see platelet-derived growth factor (PDGF)
PD-L1 (programmed cell death-I ligand-1) 91
PDE-4 277
PGE2 273
as therapy 279
pentrin 178
peristin 178–9
peroxisome proliferator-activated receptor γ (PPARγ) agonists 11
antagonists 247
PGD2 see prostaglandin D2 (PGD2)
PGF2α see prostaglandin F2α (PGF2α)
PGI2 (prostaglandin I2), airway inflammatory disease 278
phagocytosis 68
phenotype plasticity, airway smooth muscle see airway smooth muscle (ASM)
PHIL mouse 115, 117
phosphatase and tensin homolog (PTEN)
epithelial barrier 139
exogenous 300–1
HDM fecal pellets 5
see also endogenous proteases
protein kinase C inhibitors 245
pro-Th2 cytokines, blocking 8–9
protocadherin, epithelial cells 144
PRRs see pattern recognition receptors (PRRs)
PTEN see phosphatase and tensin homolog (PTEN)
pulmonary alveolar proteinosis (PAP)-like disease 189
pulmonary homeostasis, cytokines 188–9
Q
QAX576 22
R
RAG1-deficient mice, IL-13 176–7
RAG-2-deficient mice, IL-25 201
RALDH-1 (retinal dehydrogenase 1), Treg development 42
RANTES (CCL5) 254–5
rapamycin 246
rat anti-TNF-a monoclonal antibody 228
receptor tyrosine kinases (RTKs), vascular endothelial growth factor signaling 242
regulatory B cells 72–3
regulatory T cells (Tregs) 27–8, 28, 39–57, 218
allergy/asthma 44–5, 47–8
cell markers 39, 40–1, 42
corticosteroids 50–1
cytokine production 16, 21
depletion studies 44
development 3, 28, 41, 42–4
drug design 49–51
functions 40–1, 41, 42–4
studies 48
IL-10 see interleukin 10
IL-10 (IL-10) inducible 217–18, 220
localization 43
mast cell regulation 91–2
mechanisms of action 41–2
mucosal surfaces 43
TGF-β see transforming growth factor β (TGF-β)
Tr1 40–1
relaxin 154, 245
retinal dehydrogenase 1 (RALDH-1), Treg development 42
retinoic acid related orphan receptor γ (RORγt) TGF-β effects 46
Th17 cell development 28
reverse transcription polymerase chain reaction (RT-PCT),
eosinophil identification 116–17
rheumatoid arthritis, rituximab 72
Rho kinase inhibitors 167
RIG-I-like helicase receptors (RLRs) 308
rituximab, B-cell depletion 72
RLRs (RIG-I-like helicase receptors) 308
Ro 45–2081, 227, 228
roflumilast (Daxas®) 167
rolipram 167
RORγt, allergic asthma 30
RP105/MD-1 70–1
RP73401 (piclamilast) 167
RT-PCR (reverse transcription polymerase chain reaction),
eosinophil identification 116–17
rush venom immunotherapy 50
S
S–1–P, mast cell activation 93
SAM pointed domain containing ETS transcription factor (SPDEF) 140
SB-297006 259
SB-328437 259
SCHC 259
scurfy mouse 47
SD-208, airway remodeling 153
serum response factor (SRF), TGF-β signaling 152–3
severe asthma 30–1
SH (somatic hypermutation) 68–9
signaling pathways
atopy 112
IL-4 175–7
IL-9 180
IL-13 175–7
TSLP 211–12, 212
skin barriers, atopic dermatitis 111–12
skin, mast cells 94–5
SMAD blocking of 245
TGF-β signaling 238
SMAD3-deficient mice 239
smooth muscle cells (SMCs) airway remodeling 149
Th2 cytokines 17
soluble IL-4 receptor 21–2
somatic hypermutation (SH) 68–9
SPE7 130
SPINK5 gene 302
deficient mice 210
Netherton syndrome 210
src kinases, as target 130
SRF (serum response factor), TGF-β signaling 152–3
ST2, basophils 127
STAT1, IL-10 signaling 216–17
Th1 cell transfer studies 200
statins 168
super Th1 cells 31–4
asthma 32, 33
cytokines 31, 31
induction 31
infectious-type bronchial asthma 32–4
surface immunoglobulin E, basophils 123
Syk kinase inhibitors 96
as target 130, 131–2
synthetic/proliferative airway smooth muscle 163
systemic lupus erythematosus (SLE) 71
rituximab 72
T
TACE (tumor necrosis factor α [TNF-α]-converting enzyme) 226
TACE, IL-8 synthesis 266
TAK779 259
TARC see CCL17 (TARC) chemokine
T cell(s)
cytotoxic see CD8+ T cells
dendritic cell interaction 4–5
development 3, 39–40
eosinophil interaction 117
helper T cells see CD4+ T cells
T-cell receptor (TCR) 307
α chain, NKT cells 59
Th17 cell development 28
TCR see T-cell receptor (TCR)
TGF-α (transforming growth factor α), 264
TGF-β see transforming growth factor β (TGF-β)
TGF-β1 (transforming growth factor β1) 151
TGF-β2 (transforming growth factor β2) 151
Th1 cells
allergen-specific, asthma 40
asthma 27–38
cytokines see Th1 cytokines
development 28
super Th1 cells see super Th1 cells
Th1 cytokines 16
promotion of 21
see also specific cytokines
Th2 cells 15–25
activation
allergen-specific activation 69
dendritic cells 6, 8
TSLP–myeloid dendritic cells interaction 207
adoptive transfer experiments 17
allergic inflammation 7
animal models 17
basophil interaction 6, 8
cytokines see Th2 cytokines
development 28
in childhood 16
TSLP–myeloid dendritic cells interaction 207
differentiation regulation 18–19, 19
drug design 21–2
genetic polymorphisms 18
helminth infections 40
IL-25 effects 201
mast cell development 79
molecular differentiation 20–1, 20
Th2 cytokines 16–18
asthma 109
B-cell regulation 17
drug design 21–2
epithelial cells 17
smooth muscle cells 17
see also specific cytokines
Th2 memory cells 207
Th3 cells, IL-10 production 217–18
Th9 cells 28
cytokines 27–8
development 28
Th17 cells 28–31
adoptive transfer experiments 199–200
allergic diseases 29–31
asthma 29–30
see also specific diseases
asthma 27–38
severe asthma 30–1
cytokine production 16
development 28–9, 28
IL-21 effects 199
see also interleukin 10 (IL-10);
interleukin 23 (IL-23)–Th17
cell axis
T-helper cells see CD4+ T cells
theophylline 220
thermoplasty, bronchial 168
thrombin, fibroblast proliferation 156
thromboxane 273
thymic stromal lymphopoietin (TSLP) 205–14
actions of
dendritic cell activation 8
NKT cell activation 64, 206–7, 207
T-cell development 40
Th2 cell differentiation 19
animal models 210–11
diseases/disorders
allergic inflammation 205–11
asthma 210
atopic dermatitis 209–10, 209, 210
infectious-type bronchial asthma 32
innate allergic immune response 205–7
intestinal parasite infections 210–11
Netherton syndrome 210
drug design 8–9
epithelial cells 142, 144
mast cells 93, 206
myeloid dendritic cells interaction 205–6, 206, 207–10
dendritic cell activation 5, 6
epithelial cell activation 5, 142
mast cell activation 80
Th2 cell differentiation 19
agonists 5
discovery 308
experimental models 311–12
house dust mite proteases 300–1
production, basophils 125
signaling 310, 310
control 312
Toll-like receptor 5 (TLR5) 309
epithelial cells 142
Toll-like receptor 6 (TLR6) 309
mast cell activation 80
Toll-like receptor 8 (TLR8) 309
mast cell activation 80
Toll-like receptor 9 (TLR9) 309
B-cell activation 71
mast cell activation 80
Toll-like receptor 10 (TLR10) 309
mast cell activation 80
Toll-like receptor 11 (TLR11) 309
Toll receptors 308
TP receptors 277
airway smooth muscle tone 276–7
TPSAB1 gene 298
TPSAB2 gene 298
TPSADI gene 298
TPSAG1 gene 298
Tr1, Treg 40–1
transcription factors, Th2
differentiation 21
epithelial cells 142
experimental models 312
mast cell activation 80
production, basophils 125
signaling 310
control 312
see also Toll-like receptor 6 (TLR6)
Toll-like receptor 3 (TLR3) 309
epithelial cells 142
mast cell activation 80
Toll-like receptor 4 (TLR4) 70–1, 309
actions of
dendritic cell activation 5, 6
epithelial cell activation 5, 142
mast cell activation 80
Th2 cell differentiation 19
TNF-α see tumor necrosis factor α (TNF-α)
TNFR1-FcIgG1 fusion protein 228
TNX650 22
TNX-901, atopy 112–13
Toll-like receptor(s) (TLRs); specific receptors
TNF-α see tumor necrosis factor α (TNF-α)
TNF-α production, basophils 126
NFκB pathway 211
receptor 205, 206
signal transduction 211–12, 212
tight junctions 140, 266–7
apical junction complex 139
TLRs see Toll-like receptor(s) (TLRs);
specific receptors
TNF-α see tumor necrosis factor α (TNF-α)
TNFR1-FcIgG1 fusion protein 228
TNX650 22
TNX-901, atopy 112–13
Toll-like receptor(s) (TLRs) 307–16, 309
allergic inflammation 7
basophils 125
cell expression 309
characterization 308–9
epidemiologic data 311
epithelial cells 141–2
experimental models 311–12
genetic data 311
house dust mite allergens 312
house dust mite proteases 300–1
innate immunity 67, 70
NKT cell activation 64
signaling 309–10, 310
control of 311
TNF production 225
Treg development 43
see also specific receptors
Toll-like receptor 1 (TLR1) 309
mast cell activation 80
Toll-like receptor 2 (TLR2) 309
Toll-like receptor 3 (TLR3) 309
epithelial cells 142
experimental models 312
mast cell activation 80
production, basophils 125
signaling 310
control 312
see also Toll-like receptor 6 (TLR6)
Toll-like receptor 4 (TLR4) 70–1, 309
actions of
dendritic cell activation 5, 6
epithelial cell activation 5, 142
mast cell activation 80
Th2 cell differentiation 19
agonists 5
discovery 308
experimental models 311–12
house dust mite proteases 300–1
production, basophils 125
signaling 310, 310
control 312
Toll-like receptor 5 (TLR5) 309
epithelial cells 142
Toll-like receptor 6 (TLR6) 309
mast cell activation 80
signaling 310
see also Toll-like receptor 2 (TLR2)
Toll-like receptor 7 (TLR7) 309
B-cell activation 71
mast cell activation 80
Toll-like receptor 8 (TLR8) 309
B-cell activation 71
Toll-like receptor 9 (TLR9) 309
B-cell activation 71
mast cell activation 80
production, basophils 125
Toll-like receptor 10 (TLR10) 309
Toll-like receptor 11 (TLR11) 309
Toll receptors 308
TPI ASM8 192
TP receptors 277
airway smooth muscle tone 276–7
TPSAB1 gene 298
TPSAB2 gene 298
TPSADI gene 298
TPSAG1 gene 298
Tr1, Treg 40–1
transcription factors, Th2
differentiation 21
epithelial cells 142
experimental models 312
mast cell activation 80
production, basophils 125
signaling 310
control 312
transforming growth factor α (TGF-α) 264
transforming growth factor β (TGF-β)
airway remodeling 150, 238–9
asthmatic airways 44, 166
blockers 245
deletion studies 46
fibrogenesis 245
isoforms 47, 152
MAPK signaling 153
mast cell development 79
polymorphisms 239
production 238–9
signaling 152–3, 238
Th17 cell development 28
Treg effects 44, 153
transforming growth factor β1 (TGF-β1) 151
transforming growth factor β2 (TGF-β2) 151
transgenic mice
TNF blockade therapy 227
vascular endothelial growth factor 242–3
Tregs see regulatory T cells (Tregs)
trypsin, protease-activated receptors 301
tryptase 298–9
basophils 124
mast cells 267
TSLP see thymic stromal lymphopoietin (TSLP)
tumor necrosis factor α (TNF-α)
225–35
allergic asthma 226–7
blockade therapy see tumor necrosis factor α (TNF-α) blockade therapy
IL-10 effects 215
innate immune response 225
knockout mice 227
mechanisms 232
production
IgE dependence 226
macrophages 225
mast cells 80
Th17 cells 200
receptors 226
deficient mice 227
tumor necrosis factor α (TNF-α) blockade therapy 225, 228
adverse effects 225
malignancies 231
animal models 227–9
knockout animals 227
transgenic animals 227
asthma 227–31
clinical trials 229–31, 230
human studies 229–31
indications 225
isolated airway preparations 229
mechanisms 231
structures 226
see also specific therapies
tumor necrosis factor α (TNF-α)-converting enzyme (TACE) 226
2D7, basophil identification 123
U
UCB35625 259
uPA see urokinase-type plasminogen activator (uPA)
urokinase-type plasminogen activator (uPA) 153–4, 154
mast cell activation 80
urticaria, chronic 95
V
vascular cell adhesion molecule 1 (VCAM-1) 17
mast cell activation 80
vascular endothelial growth factor (VEGF) 241, 242–3
basophils 124
blocking 246
budesonide 245
VCAM-1 see vascular cell adhesion molecule 1 (VCAM-1)
VEGF see vascular endothelial growth factor (VEGF)
very late activation antigen 1 (VLA-1) 15
viral infections
in childhood 48
epithelial barrier effects 267
NKT cells–macrophage interactions 63
vitamin B12, pregnancy effects 49
vitamin D 21, 50
insufficiency, asthma 50, 51
pregnancy effects 49
vitamin E, pregnancy effects 49
VLA-1 (very late activation antigen 1) 15
W
WBB6F1-Kitw/Kitw mice 84–5
wound repair 140–1
X
Xolair® see omalizumab
Y
Y-27635 167
YKL-40/BRP-39 178
Ym1/2 178
Z
zafirlukast 290
allergic nonatopic asthma 110
zileuton 290, 291
allergic nonatopic asthma 110
zinc, pregnancy effects 49